BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18220769)

  • 1. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Brozic P; Lanisnik Risner T; Gobec S
    Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
    Hilborn E; Stål O; Jansson A
    Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
    Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
    Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
    Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
    Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
    Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
    J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
    Poirier D
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
    Tremblay MR; Poirier D
    J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
    Smuc T; Rizner TL
    Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective estrogen enzyme modulators in breast cancer: a review.
    Pasqualini JR
    Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol.
    Tremblay MR; Boivin RP; Luu-The V; Poirier D
    J Enzyme Inhib Med Chem; 2005 Apr; 20(2):153-63. PubMed ID: 15968820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.